|
Aurobindo has
registered a net profit of Rs.127 crore (Rs.103
crore) on a total income of Rs.1363 crore
(Rs.1214 crore) for the year ended 31st
March, 2004. The company has posted these
excellent results inspite of write-offs related
to manufacturing restructuring/investments,
intense R&D and enhanced staff costs related to
regulated markets. The revenue R&D costs stood
at Rs.27 crore (Rs.15 crore) while the
depreciation recorded was Rs.34 crore (Rs.23
crore) |
|
Aurobindo Pharma Ltd
has registered a consolidated net profit of
Rs.106 Crore (Rs.87 Crore) and a growth of 22%
on a total income of Rs.1615 crore (Rs.1362
crore) for the year ended 31st March
2004. During the period consolidated EBIDTA
stood at Rs.250 crore (Rs.201 crore) registering
a growth of 24%. |
|
Aurobindo recorded a
net profit of Rs.36 crore (Rs.46 crore) for the
fourth quarter ending 31st March,
2004. The Q4 results of 2003-04 are not
comparable with that of the last quarter of the
previous year since Q4 of 2002-03 included the
full year merged results of erstwhile Ranit
Pharma Ltd and Calac Private Ltd and also one
time extraordinary income of Rs.12 crore. |
Dividend
The Board of Directors has recommended a
dividend of Rs.2.25 (Rs.1.75) per share of Rs.5
each which works out to 45% (35%) for the year,
subject to the approval of the shareholders at
the ensuing AGM. |
Exports
The Company’s
exports (FOB Value) for the year amounted to
Rs.642 crore (Rs.564 crore) comprising 49% of
the total sales. |
Entry into Regulated markets
Aurobindo has emerged as a company that has
received approvals from regulatory authorities
and joined the select group of global pharma
companies with capabilities to penetrate both
regulated and semi-regulated markets. Major
milestones were crossed in the recent times.
Unit 3 facility located at Hyderabad, received
MHRA (UK) and ANVISA (Brazil) approvals in
addition to MCC (South Africa) approval. In
April 2004, the US FDA inspected Unit 1 (API)
and Unit 3 (formulations) and the Company has
not received any 483 queries either for bulk or
formulations and hence is expected to get the
product approvals in the near future. The
company has also received its first COS approval
from the EDQM (European Directorate for Quality
Medicines) |
DMFs/ANDAs filings
Aurobindo has filed 5 DMFS for US market and 16
DMFs/COS for the EU market. The company has
filed 4 ANDAs (Abbreviated New Drug
Applications). During the year the R&D Centre of
the Company has filed eleven more process
patents. The company is working towards creating
a very broad portfolio of DMFs and ANDAs in the
therapy areas of oral and injectable
cephalosporins, oral and injectable penicillins,
CNS drugs such as antidepressants,
cardiovasculars such as ace inhibitors,
cholesterol reducing drugs such as statins,
anti-diabetic drugs and other lifestyle disease
drugs in USA, Europe and various other regulated
markets. |
China
The raw material sourcing unit at China has
stabilized production. Aurobindo (Datong)
Biopharma, producing 6 APA has been recording
positive net profits consecutively in the last
three months even at the current Pen G prices
and capacities. |
Vizag unit
The facility at Pydibhimavaram (near
Visakhapatnam) is operational in its first
operational year, and has begun contributing to
cost efficiencies and economies of scale. |
Subsidiaries/ Joint ventures
The operations from subsidiaries and joint
ventures are expected to contribute to the net
profits on a consolidated basis from FY 2004-05
onwards. |
PRESS
ROOM 
